rethinkTHC Search
Menu
Study breakdown

How Cannabis Fits Into Cancer Care: Symptom Management and Beyond

ReviewModerate evidence
The takeaway

A clinical review found that cannabis may help cancer patients manage pain, nausea, appetite loss, insomnia, and depression, with emerging preclinical evidence suggesting possible direct anti-tumor effects.

Cancer patients and caregivers interested in the evidence for cannabis in cancer care.

Vaporized cannabis did not alter plasma opioid levels, suggesting safe co-use with opioid pain medications

What the researchers found

This review examined the role of cannabis in cancer care across multiple domains. For symptom management, the evidence supported cannabis use for chemotherapy-induced nausea and vomiting, appetite stimulation, pain management (potentially synergistic with opioids), and peripheral neuropathy relief.

Inhaled cannabis was found to be more effective than placebo for peripheral neuropathy, and a pharmacokinetic study showed that vaporized cannabis did not significantly alter plasma opioid levels in patients on stable opioid therapy, suggesting safe co-administration with possible synergistic pain relief.

Beyond symptoms, the review noted a growing body of preclinical research showing anti-tumor effects of cannabinoids through mechanisms involving apoptosis, anti-angiogenesis, and metastasis inhibition. However, no clinical trials had been conducted to confirm these effects in humans.

Why it matters

Cancer patients often use cannabis, with or without medical guidance. This review provides oncologists and patients with an evidence-based framework for understanding where cannabis might fit into cancer care, from well-supported symptom management to speculative anti-tumor potential.

The numbers in context

Vaporized cannabis did not produce clinically significant changes in plasma opioid levels. Multiple preclinical studies showed anti-tumor effects through apoptosis, anti-angiogenesis, and metastasis inhibition. No clinical trials on direct anti-cancer effects had been completed at the time of publication.

How the study worked

This was a clinical review article published in a medical oncology journal, synthesizing evidence from clinical trials, pharmacokinetic studies, preclinical research, and anecdotal reports about cannabis use in cancer care.

What this study cannot tell us

The review acknowledged a lack of clinical trials for direct anti-cancer effects. Anecdotal reports of remarkable responses do not constitute clinical evidence. The symptom management evidence, while more robust, still has gaps regarding optimal dosing, formulations, and patient selection.

How to read the evidence

This is a clinical review synthesizing evidence of varying quality. Symptom management evidence draws on clinical trials, while anti-tumor claims rest on preclinical data and anecdotal reports.

When this study was published

Published in 2016. Clinical trials on cannabis and cancer have continued since, though evidence for direct anti-tumor effects in humans remains limited.

The bigger picture

The review highlights a gap between preclinical promise and clinical evidence for cannabis as a direct cancer treatment. While symptom management uses are better supported, the anti-tumor findings from laboratory and animal studies continue to drive interest in clinical trials.

Questions still open

  • Will human clinical trials confirm the anti-tumor effects seen in preclinical research? What are the optimal dosing strategies for cannabis in cancer symptom management?

Common questions

Can cannabis cure cancer?
There is no clinical trial evidence that cannabis cures cancer in humans. Preclinical studies (lab and animal models) have shown anti-tumor effects, but these findings have not been confirmed in human trials. The strongest evidence supports cannabis for managing cancer-related symptoms.
Is it safe to use cannabis alongside chemotherapy?
A pharmacokinetic study cited in this review found that vaporized cannabis did not significantly alter plasma levels of opioid medications. However, interactions with specific chemotherapy drugs have not been fully studied, and patients should discuss cannabis use with their oncology team.

Read the original research

Integrating cannabis into clinical cancer care.

Current oncology (Toronto, Ont.), 23(2), S8-S14

Citation

Abrams, D I. (2016). Integrating cannabis into clinical cancer care.. Current oncology (Toronto, Ont.), 23(2), S8-S14. https://doi.org/10.3747/co.23.3099

Explore the wider topic